Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?
about
Withdrawal of anticancer therapy in advanced disease: a systematic literature reviewTrastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact.Trastuzumab beyond progression in advanced breast cancer: national guidance versus oncologist's decision.How long should we maintain anti-HER2 therapy for metastatic breast cancer patients with complete remission?
P2860
Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Continued use of trastuzumab b ...... ractice ahead of the evidence?
@ast
Continued use of trastuzumab b ...... ractice ahead of the evidence?
@en
type
label
Continued use of trastuzumab b ...... ractice ahead of the evidence?
@ast
Continued use of trastuzumab b ...... ractice ahead of the evidence?
@en
prefLabel
Continued use of trastuzumab b ...... ractice ahead of the evidence?
@ast
Continued use of trastuzumab b ...... ractice ahead of the evidence?
@en
P2093
P2860
P1433
P1476
Continued use of trastuzumab b ...... ractice ahead of the evidence?
@en
P2093
Douglas Blayney
Jane C Weeks
Joyce C Niland
Melissa E Hughes
Rebecca A Ottesen
Richard Theriault
Stephen B Edge
Yu-Ning Wong
P2860
P304
P356
10.1634/THEONCOLOGIST.2010-0360
P577
2011-03-30T00:00:00Z